Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, Balzarotti M, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka A, Ferreri AJM, Merli F, Zhao W, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel G, Jerkeman M, Di Rocco A, Stepanishyna Y, Vitolo U, Santoro A, Re A, Puccini B, Olivieri J, Petrucci L, Barrington SF, Malkowski B, Metser U, Versari A, Chauvie S, Walewski J, Trneny M, Cavalli F, Gospodarowicz M, Johnson PWM, Davies A, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Martelli M, et al. Among authors: ferreri ajm. J Clin Oncol. 2024 Dec;42(34):4071-4083. doi: 10.1200/JCO-24-01373. Epub 2024 Aug 19. J Clin Oncol. 2024. PMID: 39159403 Clinical Trial.
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.
Angelillo P, Alarcon Tomas A, Campodonico E, Novak U, Gabellier L, Blau IW, Kwon M, Ram R, Forcade E, Besley C, Vucinic V, Kröger N, Corral LL, Vydra J, Ferrari S, von Tresckow B, Rubio MT, Hernani R, Sica S, Stölzel F, Rovira M, Wagner-Drouet E, Pérez-Simón JA, Castilla-Llorente C, Ferreri AJM, Hoogenboom JD, Sanchez Ortega I, Malard F, Kuball J, Ruggeri A. Angelillo P, et al. Among authors: ferreri ajm. Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02451-8. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39455896 No abstract available.
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.
Xu-Monette ZY, Luo C, Yu L, Li Y, Bhagat G, Tzankov A, Visco C, Fan X, Dybkaer K, Sakhdari A, Wang NT, Yuan AF, Chiu A, Tam W, Zu Y, Hsi ED, Perry AM, Song W, O'Malley D, Au Q, Nunns H, Go H, Møller MB, Parsons BM, Montes-Moreno S, Ponzoni M, Ferreri AJM, Sohani AR, Abramson JS, Xu B, Young KH. Xu-Monette ZY, et al. Among authors: ferreri ajm. Oncoimmunology. 2024 Aug 5;13(1):2384667. doi: 10.1080/2162402X.2024.2384667. eCollection 2024. Oncoimmunology. 2024. PMID: 39108501 Free PMC article.
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
Pinto A, Caltagirone M, Battista M, Gazzoli GC, Patti C, Pennese E, De Lorenzo S, Pavone V, Merli M, Chiarenza A, Gorgone AG, Piazza F, Puccini B, Noto A, Arcaini L, De Filippi R, Zinzani PL, Ferreri AJM, Ladetto M, Ferrari S, Gritti G. Pinto A, et al. Among authors: ferreri ajm. Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22. Br J Haematol. 2024. PMID: 39039666 Free PMC article.
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
Pulsoni A, Ferrero S, Tosti ME, Luminari S, Dondi A, Cavallo F, Merli F, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJM, Rattotti S, Zilioli VR, Bolis SA, Bernuzzi P, Musuraca G, Gaidano G, Perrone T, Stelitano C, Tucci A, Corradini P, Bigliardi S, Re F, Cencini E, Mannarella C, Mannina D, Celli M, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Bomben R, Ciabatti E, Genuardi E, Drandi D, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. Pulsoni A, et al. Among authors: ferreri ajm. Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1. Lancet Haematol. 2024. PMID: 38937025 Clinical Trial.
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Electronic address: [email protected]. Ferreri AJM, et al. Ann Oncol. 2024 May 14:S0923-7534(23)05074-3. doi: 10.1016/j.annonc.2023.11.010. Online ahead of print. Ann Oncol. 2024. PMID: 38839484 Free article. No abstract available.
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Ferreri AJM, et al. Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38836097 Free PMC article.
Targets and treatments in primary CNS lymphoma.
von Roemeling C, Ferreri AJM, Soussain C, Tun HW, Grommes C. von Roemeling C, et al. Among authors: ferreri ajm. Leuk Lymphoma. 2024 Aug;65(8):1055-1067. doi: 10.1080/10428194.2024.2342560. Epub 2024 Apr 24. Leuk Lymphoma. 2024. PMID: 38659230 Review.
344 results